

CollPlant Holdings Ltd.

("The Company")

August 18, 2014

For the attention of
The Securities Authority
www.isa.gov.il

For the attention of
The Tel-Aviv Stock Exchange Ltd.
www.tase.co.il

Dear Sir or Madam

Re: The registration of a significant patent in Israel

The company has the honor to report that on August 17, 2014, CollPlant Ltd, a wholly owned subsidiary company of the Company ("**CollPlant**") received approval for the registration of a patent in Israel, which protects methods for the production and processing of recombinant Collagen, which is extracts from plants, whilst using sources that do not come from an animal¹. The patent that protects the said technology, is wholly owned by CollPlant. The registration of the patent, whose number is 205720, has been registered in CollPlant's name, in accordance with the application that was filed on October 26, 2008, bearing a retroactive validity as from October 25, 2007. The patent expires on October 26, 2028.

About CollPlant:

CollPlant is a medical device firm established in 2004 to focus on advancing regenerative medicine through its cutting-edge technology designed to generate and process proprietary recombinant human collagen, among other patent-protected recombinant proteins. CollPlant is developing a broad spectrum of biomaterials for a wide variety of medical markets, including orthopedics, wound healing, and general surgery. CollPlant's business model consists of own development and manufacturing of medical devices and their commercialization and distribution together with leading third parties, alongside alliances with leading companies for joint development, manufacturing and marketing of additional

¹ For additional details regarding the patent, see row 2 in the second table in Section 17.4.1 of Chapter A (Description of the Entity's business) to the Company's periodic report for the year 2013, dated March 24, 2014 [Document No. 2014-01-022545] ("**The annual report**")